These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 2365199)

  • 21. Effect of dietary fiber on serum bile acids in patients with chronic cholestatic liver disease under ursodeoxycholic acid therapy.
    Sauter G; Beuers U; Paumgartner G
    Digestion; 1995; 56(6):523-7. PubMed ID: 8536824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
    Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
    Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bile acid conjugation in early stage cholestatic liver disease before and during treatment with ursodeoxycholic acid.
    Fracchia M; Setchell KD; Crosignani A; Podda M; O'Connell N; Ferraris R; Hofmann AF; Galatola G
    Clin Chim Acta; 1996 Apr; 248(2):175-85. PubMed ID: 8740581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel and emerging therapies for cholestatic liver diseases.
    Goldstein J; Levy C
    Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ursodeoxycholic acid, 7-ketolithocholic acid, and chenodeoxycholic acid are primary bile acids of the nutria (Myocastor coypus).
    Tint GS; Bullock J; Batta AK; Shefer S; Salen G
    Gastroenterology; 1986 Mar; 90(3):702-9. PubMed ID: 3943698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol.
    Ghonem NS; Auclair AM; Hemme CL; Gallucci GM; de la Rosa Rodriguez R; Boyer JL; Assis DN
    Clin Pharmacol Ther; 2020 Dec; 108(6):1213-1223. PubMed ID: 32480421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Physico-chemical properties of ursodeoxycholic acid and its usefulness in hepatopathies].
    Méndez Sánchez N; Coté C; Aguilar Ramírez A; Uribe M
    Rev Gastroenterol Mex; 1992; 57(3):183-90. PubMed ID: 1308299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis.
    Batta AK; Salen G; Arora R; Shefer S; Tint GS; Abroon J; Eskreis D; Katz S
    Hepatology; 1989 Oct; 10(4):414-9. PubMed ID: 2777202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resolution of radiographic abnormalities with ursodeoxycholic acid therapy of primary sclerosing cholangitis.
    Lebovics E; Salama M; Elhosseiny A; Rosenthal WS
    Gastroenterology; 1992 Jun; 102(6):2143-7. PubMed ID: 1587436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three paediatric cases of primary sclerosing cholangitis treated with ursodeoxycholic acid and sulphasalazine.
    Kozaiwa K; Tajiri H; Sawada A; Tada K; Etani Y; Miki K; Okada S
    J Gastroenterol Hepatol; 1998 Aug; 13(8):825-9. PubMed ID: 9736177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis.
    Stiehl A; Rudolph G; Raedsch R; Möller B; Hopf U; Lotterer E; Bircher J; Fölsch U; Klaus J; Endele R
    Hepatology; 1990 Sep; 12(3 Pt 1):492-7. PubMed ID: 2401455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.
    Jazrawi RP; de Caestecker JS; Goggin PM; Britten AJ; Joseph AE; Maxwell JD; Northfield TC
    Gastroenterology; 1994 Jan; 106(1):134-42. PubMed ID: 8276175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
    Linares Rodríguez A
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis.
    Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
    Dig Dis Sci; 2006 Mar; 51(3):618-22. PubMed ID: 16614977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of Ursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis with Ulcerative Colitis: A Pediatric Case.
    Fujita Y; Sugaya T; Inui A; Yoshihara S
    Tohoku J Exp Med; 2021 Feb; 253(2):109-112. PubMed ID: 33551380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study.
    Fromm H; Roat JW; Gonzalez V; Sarva RP; Farivar S
    Gastroenterology; 1983 Dec; 85(6):1257-64. PubMed ID: 6354826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic approaches for hepatobiliary disorders with ursodeoxycholic acid and bile-acid derivatives.
    Serfaty L; Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S1. PubMed ID: 23141887
    [No Abstract]   [Full Text] [Related]  

  • 39. Biliary lipid metabolism in gallstone disease and during gallstone dissolution treatment.
    Nilsell K
    Acta Chir Scand Suppl; 1985; 528():1-38. PubMed ID: 3866449
    [No Abstract]   [Full Text] [Related]  

  • 40. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis.
    Sasatomi K; Noguchi K; Sakisaka S; Sata M; Tanikawa K
    J Hepatol; 1998 Sep; 29(3):409-16. PubMed ID: 9764987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.